S-8 POS 1 d800141ds8pos.htm S-8 POS S-8 POS

As filed with the Securities and Exchange Commission on November 20, 2023

Registration No. 333-270868

Registration No. 333-263241

Registration No. 333-253742

Registration No. 333-237265

Registration No. 333-230133

Registration No. 333-224942

Registration No. 333-221566

Registration No. 333-213090

Registration No. 333-192215

Registration No. 333-176934

Registration No. 333-139196

Registration No. 333-48352

 

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

POST-EFFECTIVE AMENDMENT NO. 1 TO:

FORM S-8 REGISTRATION No. 333-270868

FORM S-8 REGISTRATION No. 333-263241

FORM S-8 REGISTRATION No. 333-253742

FORM S-8 REGISTRATION No. 333-237265

FORM S-8 REGISTRATION No. 333-230133

FORM S-8 REGISTRATION No. 333-224942

FORM S-8 REGISTRATION No. 333-221566

FORM S-8 REGISTRATION No. 333-213090

FORM S-8 REGISTRATION No. 333-192215

FORM S-8 REGISTRATION No. 333-176934

FORM S-8 REGISTRATION No. 333-139196

FORM S-8 REGISTRATION No. 333-48352

Under

THE SECURITIES ACT OF 1933

 

 

ACER THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware

(State or other jurisdiction of

incorporation or organization)

  

32-0426967

(I.R.S. Employer

Identification No.)

One Gateway Center, Suite 356

300 Washington Street, Newton, MA

(Address of principal executive offices)

  

02458

(Zip Code)

Acer Therapeutics Inc. 2018 Stock Incentive Plan

Acer Therapeutics Inc. Amended and Restated 2010 Stock Incentive Plan

Acer Therapeutics Inc. 2013 Stock Incentive Plan, as amended

Amended and Restated 2010 Stock Incentive Plan

2010 Stock Incentive Plan

2004 Compensatory Stock Option Plan

June 2004 Compensatory Stock Option Plan

Thomas C. Pritchard Consulting Agreement

(Full title of the plans)

R. LaDuane Clifton, MBA, CPA

Chief Financial Officer, Secretary and Treasurer

c/o Zevra Therapeutics, Inc.

1180 Celebration Boulevard, Suite 103

Celebration, FL 34747

(Name and address of agent for service)

(321) 939-3416

(Telephone number, including area code, of agent for service)

 

 

Copy to:

Stephanie M. Hosler, Esq.

Robert J. Endicott, Esq.

Bryan Cave Leighton Paisner LLP

One Metropolitan Square

211 N. Broadway, Suite 3600

St. Louis, Missouri 63102

(314) 259-2000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐    Accelerated filer   ☐
Non-accelerated filer   ☒    Smaller reporting company   ☒
     Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

 

EXPLANATORY NOTE/DEREGISTRATION OF UNSOLD SECURITIES

Pursuant to an Agreement and Plan of Merger, dated as of August 30, 2023 (the “Merger Agreement”), by and among Zevra Therapeutics, Inc., a Delaware corporation (“Zevra”), Aspen Z Merger Sub, Inc., a Delaware corporation and an indirect wholly-owned subsidiary of Zevra (“Merger Sub”), and Acer Therapeutics Inc. (the “Registrant”), on November 17, 2023, the Merger Sub merged with and into the Registrant, with the Registrant surviving the merger as an indirect wholly-owned subsidiary of Zevra (the “Merger”). As a result of the Merger, the Registrant’s equity securities ceased to be publicly traded.

The Registrant previously registered shares of the Registrant’s common stock, $0.0001 par value per share (“Common Stock”), issuable or issued under certain employee benefit and equity plans and agreements under the below referenced Registration Statements on Form S-8 (the “Registration Statements”). As a result of the consummation of the transactions contemplated by the Merger Agreement, the Registrant has terminated all offerings of Common Stock pursuant to the below referenced Registration Statements. In accordance with an undertaking made by the Registrant in each of the Registration Statements to remove from registration by means of a post-effective amendment any securities that remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration all Common Stock that remains unsold as of the date hereof registered pursuant to the Registration Statements. Each Registration Statement is hereby amended, as appropriate, to reflect the deregistration of all such securities.

 

Registration

No.

    Date Filed
With
the SEC		   

Name of Equity Plan

    Number of
Shares of
Common
Stock
Originally
Registered		  
333-270868    03/27/2023   

Acer Therapeutics Inc. 2018 Stock Incentive Plan

      784,971  
333-263241    03/03/2022   

Acer Therapeutics Inc. 2018 Stock Incentive Plan

      772,410  
333-253742    03/01/2021   

Acer Therapeutics Inc. 2018 Stock Incentive Plan

      529,325  
333-237265    03/18/2020   

Acer Therapeutics Inc. 2018 Stock Incentive Plan

      403,807  
333-230133    03/07/2019   

Acer Therapeutics Inc. 2018 Stock Incentive Plan

      403,495  
333-224942    05/15/2018   

Acer Therapeutics Inc. 2018 Stock Incentive Plan

      500,000  
333-224942    05/15/2018   

Acer Therapeutics Inc. Amended and Restated 2010 Stock Incentive Plan

      170  
333-221566    11/14/2017   

Acer Therapeutics Inc. Amended and Restated 2010 Stock Incentive Plan

      470,000  
333-221566    11/14/2017   

Acer Therapeutics Inc. 2013 Stock Incentive Plan, as amended

      165,000  
333-213090    08/11/2016   

Amended and Restated 2010 Stock Incentive Plan

      650,000  
333-192215    11/08/2013   

Amended and Restated 2010 Stock Incentive Plan

      3,000,000  
333-176934    09/21/2011   

2010 Stock Incentive Plan

      3,085,808  
333-176934    09/21/2011   

2004 Compensatory Stock Option Plan

      514,192  
333-139196    12/08/2006   

June 2004 Compensatory Stock Option Plan

      1,200,000  
333-48352    10/20/2000   

Thomas C. Pritchard Consulting Agreement

      100,000  

SIGNATURE

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No.1 to be signed on its behalf by the undersigned, thereunto duly authorized in the city of Celebration, state of Florida, on November 20, 2023.

 

ACER THERAPEUTICS INC.
By  

/s/ R. LaDuane Clifton

  R. LaDuane Clifton
  Chief Financial Officer, Secretary and Treasurer

Note: No other person is required to sign this Post-Effective Amendment No. 1 in reliance upon Rule 478 under the Securities Act of 1933.